Halozyme Therapeutics, Inc. (HALO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
33 Pages - GLDATA50950
$250.00

Summary

Halozyme Therapeutics, Inc. (Halozyme) is a biotechnology company. It focuses on the development and commercialization of novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company’s products portfolio depends on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company’s marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics, Inc. (HALO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Halozyme Therapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Avid Bioservices Extends Manufacturing And Supply Agreement With Halozyme Therapeutics 11
Halozyme Enters Into Research Agreement With BioAtla 12
Licensing Agreements 13
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 13
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 14
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 15
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 17
Halozyme Therapeutics Enters Into Licensing Agreement With Intrexon 19
ViroPharma Enters Into Licensing Agreement With Halozyme Therapeutics 21
Equity Offering 23
Halozyme Therapeutics Completes Public Offering Of Shares For US$115 Million 23
Halozyme Completes Public Offering Of Common Stock For US$83 Million 25
Halozyme Therapeutics Completes Public Offering For US$60.1 Million 27
Halozyme Therapeutics, Inc. - Key Competitors 29
Key Employees 30
Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Halozyme Therapeutics, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Halozyme Therapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Avid Bioservices Extends Manufacturing And Supply Agreement With Halozyme Therapeutics 11
Halozyme Enters Into Research Agreement With BioAtla 12
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 13
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 14
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 15
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 17
Halozyme Therapeutics Enters Into Licensing Agreement With Intrexon 19
ViroPharma Enters Into Licensing Agreement With Halozyme Therapeutics 21
Halozyme Therapeutics Completes Public Offering Of Shares For US$115 Million 23
Halozyme Completes Public Offering Of Common Stock For US$83 Million 25
Halozyme Therapeutics Completes Public Offering For US$60.1 Million 27
Halozyme Therapeutics, Inc., Key Competitors 29
Halozyme Therapeutics, Inc., Key Employees 30
Halozyme Therapeutics, Inc., Subsidiaries 32

List of Figures
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Halozyme Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Halozyme Therapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016 9

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838